ThinkSono partners with NYU Langone Health to conduct study of Ultrasound AI Guidance Software for DVT detection

 London, UK, November 3, 2023 

ThinkSono Ltd (“ThinkSono”) a leading ultrasound AI company has partnered with NYU Langone Health as a trial site to launch the first U.S. based clinical trial of ThinkSono Guidance – a new artificial intelligence (AI)-powered ultrasound software that enables more rapid and portable diagnosis of deep vein thrombosis (DVT). 

 DVT: A leading cause of preventable hospital death [1] 

DVT, a condition in which blood clots develop in veins, affects up to 300,000 Americans every year and is common in hospitalized patients. [2] DVT can lead to potentially fatal complications like the spread of blood clots to the heart and lungs (known as pulmonary embolism, PE) as well as debilitating long-term swelling and pain of the legs (called post-thrombotic syndrome). [3] DVT is also a significant driver of healthcare costs, costing the U.S. healthcare system up to $10 billion each year. [4] NYU Langone’s vascular surgeons are experts in the treatment of these conditions, with extensive experience in conducting clinical trials. 

The ThinkSono Guidance System technology leverages the power of AI to potentially detect DVT more quickly, accurately, and cost-effectively compared to traditional methods. 

“We’re tackling a major issue that can affect a wide range of patients,” notes Dr. Glenn Jacobowitz, the Frank J. Veith, MD Professor of Vascular and Endovascular Surgery at NYU Langone and a world-renowned expert on venous disease. 

Dr Jacobowitz, who is President of the American Venous Forum and principal investigator for the NYU Langone study, notes that “an effective ultrasound guidance technology would be a powerful tool in our diagnostic arsenal. It’s the kind of innovation through which NYU Langone can literally change the way high-quality, efficient care is delivered to patients on a daily basis. The potential impact in the U.S. and abroad is enormous.” 

Researchers will perform traditional ultrasound scans in patients with and without DVT, as well as ThinkSono Guidance System scans. The performance of both methods will be compared to assess and validate the accuracy of the ThinkSono system. 

Medical students from the NYU Grossman School of Medicine will also aid in conducting the trial as a part of the school’s hands-on research curriculum. Giancarlo Speranza and Keerthi Harish are two medical students at NYU’s joint MD/MBA program participating in the study. 

“This opportunity captures a lot of what our program is about- clinical excellence, innovative thinking, and doing good for our patients,” notes Speranza. “The chance to impact the field on this scale is why I chose NYU Grossman.” 

Harish adds, “One of the exciting aspects of this study is that we will be able to better understand not only how this technology performs but how AI-enabled solutions can be implemented in real-world clinical settings.” 

The research team hopes to conclude the study and publish the results in the coming year, in preparation for subsequent FDA submission. 

“We always aim to have our research translate into tangible, real-world effects,” says Dr. Thomas Maldonado, Medical Director of the NYU Langone Venous Thromboembolic Center. “With this trial, we can help patients and develop the next generation of physician-leaders.” 

Fouad Al Noor, CEO of ThinkSono, added, “I’m very pleased with the partnership we have with NYU Langone Health and it shows how forward-thinking the institution is by trialing cutting-edge AI technologies that may benefit patients, providers, and ultimately patient lives.” 

Image showing NYU researchers (left: Moira McGevna, right: Giancarlo Speranza, not pictured: Dr. Amir Mullick, Gina Bernardez, Keerthi Harish, Dr Glenn Jacobowitz) with ThinkSono Guidance App (right) [5] and a compatible handheld ultrasound device (left) [6] 

About ThinkSono 

Founded in 2016, ThinkSono ( has developed the world’s first real-time Ultrasound AI software to enable non-ultrasound healthcare staff to perform DVT scans. This technology addresses the worldwide unmet medical need for better DVT detection. 

Furthermore, ThinkSono is developing training solutions for other ultrasound AI applications which aims to increase access to ultrasound imaging and upskilling non-ultrasound trained healthcare staff to perform key ultrasound scans. ThinkSono’s DVT solution has already been trialed in hospitals across the UK, EU and is now expanding into the U.S. 

With several patents granted and multiple peer-reviewed papers published in prominent journals such as Nature Digital Medicine, ThinkSono has demonstrated its leadership in the Ultrasound AI space. The company aims to enable any healthcare professional to use the power of ultrasound to diagnose disease and increase the universal access to ultrasound imaging. 

Media Contact: 

About NYU Langone Health 

NYU Langone Health is one of the largest healthcare systems in the Northeast, with more than 46,000 employees. NYU Langone Health is ranked #3 in the nation and #1 in New York State on U.S. News & World Report’s 2022–23 “Best Hospitals Honor Roll.” 


[1] Note: Deaths related to venous thromboembolism (VTE) which is DVT and PE combined. As per the Centers for Disease Control and Prevention (CDC). Society of Hospital Medicine, Maynard GA, Stein JM, US Agency for Healthcare Research and Quality. Preventing hospital-acquired venous thromboembolism: a guide for effective quality improvement. Rockville, MD: Agency for Healthcare Research and Quality, US Dept. of Health and Human Services; 2008. 

[2] VTE in Cancer Patients [Internet]. London: All-Party Parliamentary Thrombosis Group; 2015 [cited 2023 May 8]. Available from: content/uploads/2016/12/VTE-in-Cancer-Patients-2015.pdf. 

[3] Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need  for progress. Br J Haematol. 2009 May;145(3):286-95. doi: 10.1111/j.1365-2141.2009.07601.x. Epub 2009 Feb 13. PMID: 19222476. 

[4] Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden  of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan;137:3-10. doi: 10.1016/j.thromres.2015.11.033. Epub 2015 Nov 24. PMID: 26654719; PMCID: PMC4706477.